This information is issued on behalf of Highmark Blue Shield and its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association. Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in 21 counties in central Pennsylvania and 13 counties in northeastern New York. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania. Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware and 8 counties in western New York. All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies.

Population Health University

Population Health University is an open exchange of information with The American Journal of Managed Care® (AJMC®) designed to deliver valuable information to you so that you can improve your overall delivery of care.

Regions of Highmark


Latest from Highmark

Alignment Between Manufacturers, Payers Key to Improving Specialty Drug Affordability and Access

June 22, 2022

Panelists taking part in an AHIP 2022 session discuss collaborative strategies among payers, manufacturers, and policy makers to address challenges regarding affordability and access of novel disease modifying drugs entering the marketplace.

What We’re Reading: Combating Drug Prices; Fauci Warns on Delta Variant; Health Care Gaps

June 23, 2021

Blue Cross Blue Shield aims to fight increasing drug prices with a new pharmacy solutions company; Anthony Fauci, MD, warns about the growing threat from the Delta variant; COVID-19–related death rates highest in Texas border counties.

Empagliflozin Linked to 20% Drop in Care Costs for T2D, CVD

December 15, 2020

An outcomes-based agreement conducted by Boehringer Ingelheim and Highmark found that use of Jardiance (empagliflozin) among adults with type 2 diabetes (T2D) and known cardiovascular disease (CVD) was associated with a total cost of care savings of over 20%.